These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20736989)

  • 21. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.
    Drevets WC; Zarate CA; Furey ML
    Biol Psychiatry; 2013 Jun; 73(12):1156-63. PubMed ID: 23200525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
    Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
    CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neural correlates of rapid antidepressant response to ketamine in bipolar disorder.
    Nugent AC; Diazgranados N; Carlson PJ; Ibrahim L; Luckenbaugh DA; Brutsche N; Herscovitch P; Drevets WC; Zarate CA
    Bipolar Disord; 2014 Mar; 16(2):119-28. PubMed ID: 24103187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
    Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
    Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
    Ballard ED; Luckenbaugh DA; Richards EM; Walls TL; Brutsché NE; Ameli R; Niciu MJ; Vande Voort JL; Zarate CA
    J Psychiatr Res; 2015 Sep; 68():68-73. PubMed ID: 26228403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression: A Randomized Clinical Trial.
    McIntyre RS; Subramaniapillai M; Lee Y; Pan Z; Carmona NE; Shekotikhina M; Rosenblat JD; Brietzke E; Soczynska JK; Cosgrove VE; Miller S; Fischer EG; Kramer NE; Dunlap K; Suppes T; Mansur RB
    JAMA Psychiatry; 2019 Aug; 76(8):783-790. PubMed ID: 31066887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulsed intravenous administration of scopolamine produces rapid antidepressant effects and modest side effects.
    Furey ML; Zarate CA
    J Clin Psychiatry; 2013 Aug; 74(8):850-1. PubMed ID: 24021505
    [No Abstract]   [Full Text] [Related]  

  • 32. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
    Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of anticonvulsant ethosuximide for major depressive disorder: a randomized, placebo-control clinical trial.
    Zhang K; Jia G; Xia L; Du J; Gai G; Wang Z; Cao L; Zhang F; Tao R; Liu H; Hashimoto K; Wang G
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):487-493. PubMed ID: 32006087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression.
    Keitner GI; Garlow SJ; Ryan CE; Ninan PT; Solomon DA; Nemeroff CB; Keller MB
    J Psychiatr Res; 2009 Jan; 43(3):205-14. PubMed ID: 18586273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression.
    Calabrese JR; Keck PE; Macfadden W; Minkwitz M; Ketter TA; Weisler RH; Cutler AJ; McCoy R; Wilson E; Mullen J
    Am J Psychiatry; 2005 Jul; 162(7):1351-60. PubMed ID: 15994719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder.
    Mathew SJ; Gueorguieva R; Brandt C; Fava M; Sanacora G
    Neuropsychopharmacology; 2017 Dec; 42(13):2567-2574. PubMed ID: 28553836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
    Savitz JB; Teague TK; Misaki M; Macaluso M; Wurfel BE; Meyer M; Drevets D; Yates W; Gleason O; Drevets WC; Preskorn SH
    Transl Psychiatry; 2018 Jan; 8(1):27. PubMed ID: 29362444
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.
    Kornstein SG; Clayton AH; Bao W; Guico-Pabia CJ
    J Womens Health (Larchmt); 2015 Apr; 24(4):281-90. PubMed ID: 25860107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study.
    Loebel A; Cucchiaro J; Silva R; Kroger H; Hsu J; Sarma K; Sachs G
    Am J Psychiatry; 2014 Feb; 171(2):160-8. PubMed ID: 24170180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis.
    Khan A; Brodhead AE; Kolts RL
    Int Clin Psychopharmacol; 2004 May; 19(3):157-60. PubMed ID: 15107658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.